Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
RR 5 [0.25, 101.81]
110 participants
Very low
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes serious adverse events compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review